GlassScriptPhysician profile
Michael Colucciello
NPI 1215934146
$3,806.26
in general payments reported to CMS, 2019-2025
14 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $1,953 · 2021: $90.91 · 2022: $323 · 2023: $712 · 2024: $305 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730 · Consulting Fee: $500 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.50 |
| Consulting Fee | $500.00 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Lupin INC. | $500.00 | 2023 | |
| Allergan, INC. | $349.99 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $334.25 | 2020-2025 | Eylea, Eylea Hd |
| Genentech USA, INC. | $291.63 | 2019-2024 | Susvimo, Vabysmo |
| Alimera Sciences, INC. | $185.67 | 2019-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $181.29 | 2022-2023 | |
| Abbvie INC. | $100.17 | 2022-2025 | |
| Biogen, INC. | $79.80 | 2022 | |
| Ani Pharmaceuticals, INC. | $67.75 | 2024-2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $53.80 | 2023-2025 | Syfovre |
| Coherus Oncology, INC. | $36.45 | 2023 | |
| Harrow Eye, LLC | $36.45 | 2024-2025 | Iheezo, Vevye |
| Novartis Pharmaceuticals Corporation | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Colucciello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.